

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT

FIRST VISIT FOR THE FIRST SUBJECT COMPLETED IN PHASE I MULTIPLE ASCENDING DOSE STUDY OF LAE102 FOR THE TREATMENT OF OBESITY

This announcement is made by Laekna, Inc. (the “**Company**“, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the “**Board**”) of directors of the Company (the “**Directors**”) is pleased to announce that the Group has commenced study recruitment in phase I multiple ascending dose study (the “**MAD Study**”) of LAE102 in China for the treatment of obesity. As of the date of this announcement, the first visit for the first subject has been completed.

The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects.

The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.

About LAE102

LAE102 is an internally discovered monoclonal antibody selectively targeting ActRIIA, a receptor that plays an important role in muscle regeneration and lipid metabolism. In the pre-clinical models, LAE102 has been shown to increase lean mass and decrease fat mass. In combination with GLP1R agonist, LAE102 can further reduce fat mass and significantly regain the lean mass loss induced by GLP1R agonist. This positions LAE102 as a promising drug candidate for achieving quality weight control.

RISK WARNING

LAE102 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, March 26, 2025

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.